{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:46:20Z","timestamp":1777671980841,"version":"3.51.4"},"reference-count":6,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine High Impact Case Reports"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.<\/jats:p>","DOI":"10.1177\/23247096221123144","type":"journal-article","created":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T07:30:30Z","timestamp":1662190230000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp"],"prefix":"10.1177","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-7703","authenticated-orcid":false,"given":"Leah M.","family":"Grant","sequence":"first","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Orenstein","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,9,3]]},"reference":[{"key":"bibr1-23247096221123144","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2017.08.010."},{"key":"bibr2-23247096221123144","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1476490."},{"key":"bibr3-23247096221123144","doi-asserted-by":"publisher","DOI":"10.1086\/596757."},{"key":"bibr4-23247096221123144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033114."},{"key":"bibr5-23247096221123144","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz083."},{"key":"bibr6-23247096221123144","unstructured":"Scynexis, Inc. Investigator\u2019s Brochure: Ibrexafungerp. Jersey City, NJ: Scynexis, Inc; 2020."}],"container-title":["Journal of Investigative Medicine High Impact Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23247096221123144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23247096221123144","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23247096221123144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:03:02Z","timestamp":1777449782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23247096221123144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":6,"alternative-id":["10.1177\/23247096221123144"],"URL":"https:\/\/doi.org\/10.1177\/23247096221123144","relation":{},"ISSN":["2324-7096","2324-7096"],"issn-type":[{"value":"2324-7096","type":"print"},{"value":"2324-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"23247096221123144"}}